Broncus Holding Corporation announced that its BroncTarget® Targeted Lung Denervation Radiofrequency Ablation System has officially entered the Innovative Medical Device Special Review Procedure of the National Medical Products Administration (NMPA) of China. The system, disclosed as the "Pulmonary Radiofrequency Ablation System" in the NMPA public notice, is recognized for its technological originality and clinical value. The confirmatory clinical trial for the BroncTarget® System is currently underway, involving 28 hospitals across China for patient recruitment. There is no assurance that the system will ultimately be successfully developed and marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Broncus Holding Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260112-11988241), on January 12, 2026, and is solely responsible for the information contained therein.